An Open-label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 Nov 2016
At a glance
- Drugs Linaclotide (Primary)
- Indications Constipation; Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Allergan; Forest Laboratories
- 11 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 12 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 02 Nov 2015 New trial record